Drug Trial Radar · NCT05278975
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Mar 31, 2022
Primary completion
Nov 30, 2025
Study completion May 7, 2026
Sponsor
- Lead sponsor
- RS Oncology LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RSO-021 after intrapleural (IP) administration in patients with malignant pleural effusion (MPE) (non-mesothelioma) and MPE from mesothelioma.
Conditions
- Malignant Pleural Effusion
- Malignant Pleural Mesothelioma
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma; Lung
- Pleural Effusion, Malignant
Interventions
RSO-021Drug
A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting ToxicityTime frame: First 21 days of treatment.
- Frequency and Severity of Adverse Events (AE)Time frame: Screening to 90 days from last dose.
- Dose FindingTime frame: Screening to 90 days from last dose.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
NHS Greater Glasgow & Clyde
Glasgow, United Kingdom
Facility: HOPE Clinical Trials Facility, Leicester Royal Infirmary
Leicester, United Kingdom
Barts Health NHS Cancer Institute
London, United Kingdom
Guys and St Thomas NHS Foundation Trust
London, United Kingdom
The Royal Marsden
London, United Kingdom
The Christie NHS
Manchester, United Kingdom
Oxford University Hospitals NHS Foundation
Oxford, United Kingdom
South Mead North Bristol Hopsital
Bristol, Bristol, United Kingdom
Leeds Teaching Hospital
Leeds, Leeds, United Kingdom
Northumbria NorthTyne Side General Hospital
North Shields, North Shields, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.